Literature DB >> 16793202

A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma.

Wichuda Bamrungphon1, Nalinee Prempracha, Nophawan Bunchu, Samreung Rangdaeng, Trichak Sandhu, Songphol Srisukho, Chanchai Boonla, Sopit Wongkham.   

Abstract

We have previously used agarose gel electrophoresis and immunoblotting to qualitatively measure serum MUC5AC mucin for diagnosing cholangiocarcinoma. In this study, we developed a quantitative determination of serum MUC5AC by sandwich ELISA using MUC5AC mucin monoclonal antibody and soybean agglutinin. A cut-off value of the absorbance 0.074 was obtained from a complete statistical Receiver Operating Characteristic curves with an area under the curve=0.8141. The assay could discriminate cholangiocarcinoma patients from the controls with 71% sensitivity and 90% specificity. The test is simple to perform, reproducible, and probably used for detecting cholangiocarcinoma in a high-risk group or suspected patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793202     DOI: 10.1016/j.canlet.2006.05.007

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  19 in total

Review 1.  Cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Ghulam Abbas; Keith D Lindor
Journal:  J Gastrointest Cancer       Date:  2009-08-25

Review 2.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

3.  Triple modality testing by endoscopic retrograde cholangiopancreatography for the diagnosis of cholangiocarcinoma.

Authors:  Arjun Nanda; Jason M Brown; Stephen H Berger; Melinda M Lewis; Emily G Barr Fritcher; Gregory J Gores; Steven A Keilin; Kevin E Woods; Qiang Cai; Field F Willingham
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

Review 4.  Molecular diagnosis of intrahepatic cholangiocarcinoma.

Authors:  Hiroaki Haga; Tushar Patel
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-09-29       Impact factor: 7.027

Review 5.  Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy.

Authors:  Domenico Viterbo; Valerie Gausman; Tamas Gonda
Journal:  World J Gastrointest Endosc       Date:  2016-02-10

Review 6.  Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches.

Authors:  Atit Silsirivanit; Kanlayanee Sawanyawisuth; Gregory J Riggins; Chaisiri Wongkham
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-02-12       Impact factor: 7.027

7.  New insights on cholangiocarcinoma.

Authors:  Manuela Gatto; Domenico Alvaro
Journal:  World J Gastrointest Oncol       Date:  2010-03-15

8.  Diagnosis of cholangiocarcinoma.

Authors:  B E Van Beers
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

Review 9.  The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer.

Authors:  Banchob Sripa; Paul J Brindley; Jason Mulvenna; Thewarach Laha; Michael J Smout; Eimorn Mairiang; Jeffrey M Bethony; Alex Loukas
Journal:  Trends Parasitol       Date:  2012-09-01

Review 10.  Current and future roles of mucins in cholangiocarcinoma-recent evidences for a possible interplay with bile acids.

Authors:  Elisa Danese; Andrea Ruzzenente; Martina Montagnana; Patricia Marie-Jeanne Lievens
Journal:  Ann Transl Med       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.